Public Relations

Sponsored Research Projects

AB-BIOTICS S.A. participates in the RIS3CAT project COMRDI15-1-0029: New modulating ingredients of the microbiota applying the omics and big data biotechnology, which has been co-financed by the European Union through the European Regional Development Fund (FEDER, Fondo Europeo de Desarrollo Regional- in Spanish).

Main goal of the project is to promote technological development, innovation and high quality research. A symbiotic formula contaning fibers and a mix of L. brevis and L. plantarum was developed to test in patients with chronic kidney disease.

AB-BIOTICS develops the project “BRAINMETS: Nous biomarcadors per detecció precoç de metàstasi cerebral en càncer de mama“, based on a collaboration with researchers from Hospital Clínic de Barcelona-IDIBAPS. The project has received funding from ACCIÓ, with number of file PAT15-1-0018.

AB-BIOTICS SA in cooperation with the private foundation CAIXA AIDS Research Institute participates in the project RESEARCH AND DEVELOPMENT OF A NEW THERAPY FOR THE RECONSTRUCTION OF INTESTINAL MICROBIOMY IN HIV + IMMUNODISCORDANT PATIENTS with funding from the Ministry of Science, Research and Universities, through the program RETOS in Collaboration program and whose file is RTC-20016-5113-1.The project has been co-financed by the Euro-European Union, through the European Regional Development Fund (FEDER, Fondo Europeo de Desarrollo Regional-in Spanish).

AB-BIOTICS S.A. in cooperation with the FUNDACIÓN PARA LA INVESTIGACIÓN BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL participates in the Research project of a microorganism with the capacity to degrade gluten as well as other immunotoxic peptides from other cereals, and its development and clinical validation as a pharmaceutical product for the celiac disease, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose file number is the RTC-2015-3440-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

AB-BIOTICS S.A. coordinates the project Development of combined nutritional therapies for the treatment of ulcerative colitis by increasing the biodiversity of the microbiota, in collaboration with the HOSPITAL UNIVERSITARI HOSPITAL VALL D’HEBRON and the FUNDACIÓN PARA INVESTIGACIÓN BIOMÉDICA HOSPITAL GREGORIO MARAÑON. The project has received funding from the Ministry of Science, Innovation and Universities through the Challenges in Collaboration Program and whose file number is the RTC-2015-3548-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

AB-BIOTICS S.A. in cooperation with the BOSCH I GIMPERA FOUNDATION, they are investigating within the framework of the multigenic Predictor project for the prevention of secondary effects induced by antipsychotics – APSIDE, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose file number is the RTC-2015-3440-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

AB-BIOTICS S.A. in cooperation with the FOUNDATION FOR THE PROMOTION OF HEALTH AND BIOMEDICAL RESEARCH IN THE VALENCIAN COMMUNITY, they have started the research project Development of Streptococcus dentisani as probiotic anticaries, with funding from the Ministry of Science, Innovation and Universities, through the Challenges in Collaboration Program and whose number of file is the RTC-2015-4292-1. The project has been co-financed by the European Union, as it is a Program that is aligned with the following Thematic Objective of the Operational Program: Promoting technological development, innovation and quality research.

AB-BIOTICS S.A. participates in the project eResponse: Prediction software for response to pharmacological treatments for the eReport platform, file TSI-100700-2014-10, developed jointly with the company ORYZON GENOMICS DIAGNOSTICO SL, which is being co-financed by the Ministry of Industry , Energy and Tourism, within the National Plan for Scientific Research, Development and Technological Innovation 2013-2016.

AB-BIOTICS S.A. participates in the InteliGEN Suite project: Development of a dynamic pharmacogenetic platform for depression, file TSI-020605-2012-56, developed jointly by the companies ASCIDEA COMPUTATIONAL BIOLOGY SOLUTIONS S.L., STACKOPS TECHNOLOGIES S.L. and PASSWORDBANK TECHNOLOGIES S.L. (currently Mas Movil Telecom 3.0 S.A.), which is being co-financed by the Ministry of Industry, Energy and Tourism, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011.

Ticker name: ABB:SM
Fusion by absorption AB-BIOTICS – ALIFARM (ES)

PUBLICIDAD DEL PROYECTO COMÚN DE FUSIÓN POR ABSORCIÓN

SOCIEDAD ABSORBENTE: AB-BIOTICS, S.A.

SOCIEDAD ABSORBIDA: ALIFARM, S.A.U.

En cumplimiento de lo dispuesto en el artículo 32 de la Ley 3/2009, de 3 de abril, sobre Modificaciones Estructurales de las Sociedades Mercantiles (en adelante LME), se procede a dar publicidad al PROYECTO COMÚN DE FUSIÓN POR ABSORCIÓN, redactado y suscrito con fecha 15 de marzo de 2022 por los miembros de los órganos de administración de AB-BIOTICS, S.A. (sociedad absorbente), y de su filial íntegramente participada ALIFARM, S.A.U. (sociedad absorbida). En virtud de dicho proyecto de fusión se proyecta la absorción de ALIFARM, S.A.U. mediante su disolución sin liquidación, con la transmisión en bloque y a título universal de su patrimonio social a AB-BIOTICS, S.A., como sociedad absorbente, la cual quedará subrogada en la titularidad de todos los derechos y obligaciones de la sociedad absorbida. Todo ello con arreglo a los balances de fusión cerrados a 31 de diciembre de 2021 y a lo establecido en el proyecto de fusión que se publica junto con el presente anuncio.​

A estos efectos, AB-BIOTICS, S.A. presentará la correspondiente certificación en el Registro Mercantil de Barcelona con el objeto de que el hecho de la inserción del PROYECTO COMÚN DE FUSIÓN POR ABSORCIÓN en la página web se publique en el Boletín Oficial del Registro Mercantil, con expresión de la página web corporativa de la sociedad absorbente, así como la fecha de su inserción.

Por su parte, toda vez que la sociedad absorbida, ALIFARM, S.A.U., carece de página web, los administradores mancomunados de la misma depositarán el PROYECTO COMÚN DE FUSIÓN POR ABSORCIÓN en el Registro Mercantil de Barcelona en cumplimiento de lo dispuesto en el artículo 32.2 LME. El hecho del depósito, así como la fecha en que tenga lugar, se harán constar asimismo en el Boletín Oficial del Registro Mercantil.

En Sant Cugat del Vallés (Barcelona), a 4 de abril de 2022.

Documentación de la fusión entre AB-Biotics y Alifarm (artículo 39 Ley 3/2009)

Investors Events